Thailand's first AstraZeneca vaccine exports to Philippines delayed

MANILA (Reuters): Delivery to the Philippines of the first batches of a promised 17 million doses of Thai-made AstraZeneca vaccines has been delayed by several weeks and reduced in size, a Philippine presidential adviser said on Tuesday (June 1).

The delay raises questions about AstraZeneca's vaccine distribution plan in Southeast Asia, which depends on 200 million doses made in Thailand by Siam Bioscience, a company owned by the country's king that is making vaccines for the first time.

It was not immediately clear if other countries slated to received Thai vaccine exports would be affected by similar delays.

AstraZeneca and Siam Bioscience did not immediately reply to questions about production at the Thai plant.

Inside Thailand, questions about Siam Bioscience meeting production targets are extremely sensitive because King Maha Vajiralongkorn is sole owner of the company.

Insulting Thailand's monarchy is a crime punishable by up to 15 years in prison.

Philippines presidential adviser Joey Concepcion, who has been coordinating vaccine procurement with the Philippine government and private sector, told Reuters that AstraZeneca had informed him that delivery of the first batch of 1.3 million doses would have to be pushed back from the third week of June to mid-July and also reduced to 1.17 million doses.

Concepcion said he was in touch daily with AstraZeneca and was told there were delays in Thai production.

"It is a new plant they are running... that is how it is when you start a new plant," he said.

He added that delivery of the Philippines second batch of 1.3 million doses would also be reduced to 1.17 million and has been moved from July to August.

Nearly 4 million people in the Philippines have received a first dose of a Covid-19 vaccine.

The Philippines is one of the worst-hit countries in Asia, with more than 1.2 million coronavirus cases and 21,000 deaths. It aims to inoculate at least 50 million of its 110 million population this year.

Thailand's Siam Bioscience last year signed a technology transfer agreement with AstraZeneca to produce 200 million doses per year, with 61 million doses going to Thailand this year and the rest to other Southeast Asian countries.

Thailand's mass vaccination campaign will kick off next week with no clear indication about Siam Bioscience's production volume. Public concern about vaccine access has grown in recent weeks as Thailand suffers its most severe Covid-19 outbreak yet.

Thai Health Minister Anutin Charnvirakul on Tuesday said the 6 million AstraZeneca doses due for June would be delivered on time, but did not specify how many would be from Siam Bioscience as originally planned.

Thai police earlier this year laid criminal royal insult charges against opposition figure Thanathorn Juangroongruangkit, saying he had defamed the monarchy in a Facebook Live stream when he accused the government of mishandling the vaccine campaign and of giving an unfair advantage to Siam Bioscience.

Thanathorn's case is pending trial.

Article type: metered
User Type: anonymous web
User Status:
Campaign ID: -1
Cxense type: NA
User access status: 3
Join our Telegram channel to get our Evening Alerts and breaking news highlights

Philipines , Thailand , AstraZeneca , delay , vaccine , covid-19


Next In Aseanplus News

Asean News Headlines as at 8pm on Thursday (June 24)
UN humanitarian agency says 230, 000 displaced in Myanmar this year
Philippines logs 6, 043 new Covid-19 cases, death toll tops 24, 000
Indonesia's Indosat Ooredoo launches first 5G service in Solo
Vietnam reports 285 new Covid-19 infections
No cases of Delta Plus Covid-19 variant detected in Singapore
China's crypto-miners look abroad as regulators tighten noose
Jokowi refuses to lock down as daily Covid-19 cases soar past 15, 000
Lao capital to vaccinate 80 per cent of residents against Covid-19 this year
Singapore on track to raise dining in group limit from 2 to 5 from mid-July

Stories You'll Enjoy